Dapagliflozin, a pharmacological agent known for its capacity to diminish hyperinsulinemia while promoting weight loss, has demonstrated the ability to augment insulin clearance, consequently leading to a further decline in systemic insulin concentrations [80]. This evidence concerns the gene INS and hyperinsulinism.